Literature DB >> 11841962

Endocrine sequelae in survivors of childhood cancer.

Sharon E Oberfield1, Charles A Sklar.   

Abstract

Long-term survival after treatment for childhood cancers has dramatically improved in the past 25 years. Overall 5-year survival rates for childhood cancer are greater than 70%. Residual endocrine disorders are as high as 40% in this population, with the most serious disturbances noted in growth and thyroid function. Dysfunction also is observed in the hypothalamic-pituitary-adrenal axis and the hypothalamic-pituitary-gonadal axis, and recent evidence cites alterations in bone and mineral metabolism, body composition, and lipid disorders. These abnormalities are most likely related directly to prior cancer treatment. This chapter focuses on a description of such disorders and offers suggestions for long-term endocrine management and follow-up evaluation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11841962

Source DB:  PubMed          Journal:  Adolesc Med        ISSN: 1041-3499


  12 in total

Review 1.  Pediatric brain tumor treatment: growth consequences and their management.

Authors:  Sogol Mostoufi-Moab; Adda Grimberg
Journal:  Pediatr Endocrinol Rev       Date:  2010-09

2.  Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.

Authors:  Eric J Chow; Debra L Friedman; Yutaka Yasui; John A Whitton; Marilyn Stovall; Leslie L Robison; Charles A Sklar
Journal:  J Pediatr       Date:  2007-04       Impact factor: 4.406

Review 3.  Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.

Authors:  Kirsten K Ness; Saro H Armenian; Nina Kadan-Lottick; James G Gurney
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

Review 4.  Late Cardiotoxicity: Issues for Childhood Cancer Survivors.

Authors:  Jyothsna Akam-Venkata; Vivian I Franco; Steven E Lipshultz
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-07

5.  Parenting a child with cancer: a couple-based approach.

Authors:  Laura S Porter; Donald H Baucom; Melanie Bonner; Corinne Linardic; Anne E Kazak
Journal:  Transl Behav Med       Date:  2019-05-16       Impact factor: 3.046

6.  Final height and insulin-like growth factor-1 in children with medulloblastoma treated with growth hormone.

Authors:  Hyun Wook Chae; Young Seok Park; Dong Seok Kim; Ah Reum Kwon; Ho-Seong Kim; Duk Hee Kim
Journal:  Childs Nerv Syst       Date:  2013-06-18       Impact factor: 1.475

7.  Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment.

Authors:  Shashi Raj; Vivian I Franco; Steven E Lipshultz
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-06

8.  Canadian Study of Determinants of Endometabolic Health in ChIlDrEn (CanDECIDE study): a cohort study protocol examining the mechanisms of obesity in survivors of childhood brain tumours.

Authors:  M Constantine Samaan; Lehana Thabane; Sarah Burrow; Rejane F Dillenburg; Katrin Scheinemann
Journal:  BMJ Open       Date:  2013-06-20       Impact factor: 2.692

9.  The effectiveness of interventions to treat obesity in survivors of childhood brain tumors: a systematic review protocol.

Authors:  Kuan-Wen Wang; Marlie Valencia; Laura Banfield; Ruth Chau; Adam Fleming; Sheila K Singh; Sarah Burrow; Russell J de Souza; Lehana Thabane; M Constantine Samaan
Journal:  Syst Rev       Date:  2016-06-14

10.  Recruitment feasibility to a cohort study of endocrine and metabolic health among survivors of childhood brain tumours: a report from the Canadian study of Determinants of Endometabolic Health in ChIlDrEn (CanDECIDE).

Authors:  M Constantine Samaan; Katrin Scheinemann; Sarah Burrow; Rejane F Dillenburg; Ronald D Barr; Kuan-Wen Wang; Marlie Valencia; Lehana Thabane
Journal:  BMJ Open       Date:  2014-06-26       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.